We provide you with 20 years of free, institutional-grade data for BIIB stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of BIIB. Explore the full financial landscape of BIIB stock.
| Reported Date | CIK | Ticker | Type | |
|---|---|---|---|---|
| 2025-07-31 | 875045 | BIIB | 10-Q | Url |
| 2025-05-01 | 875045 | BIIB | 10-Q | Url |
| 2025-02-12 | 875045 | BIIB | 10-K | Url |
| 2024-10-30 | 875045 | BIIB | 10-Q | Url |
| 2024-08-01 | 875045 | BIIB | 10-Q | Url |
| 2024-04-24 | 875045 | BIIB | 10-Q | Url |
| 2024-02-14 | 875045 | BIIB | 10-K | Url |
| 2023-11-08 | 875045 | BIIB | 10-Q | Url |
| 2023-07-25 | 875045 | BIIB | 10-Q | Url |
| 2023-04-25 | 875045 | BIIB | 10-Q | Url |
| 2023-02-15 | 875045 | BIIB | 10-K | Url |
| 2022-10-25 | 875045 | BIIB | 10-Q | Url |
| 2022-07-20 | 875045 | BIIB | 10-Q | Url |
| 2022-05-03 | 875045 | BIIB | 10-Q | Url |
| 2022-02-03 | 875045 | BIIB | 10-K | Url |
| 2021-10-20 | 875045 | BIIB | 10-Q | Url |
| 2021-07-22 | 875045 | BIIB | 10-Q | Url |
| 2021-04-22 | 875045 | BIIB | 10-Q | Url |
| 2021-02-03 | 875045 | BIIB | 10-K | Url |
| 2020-10-21 | 875045 | BIIB | 10-Q | Url |
| 2020-07-22 | 875045 | BIIB | 10-Q | Url |
| 2020-04-23 | 875045 | BIIB | 10-Q | Url |
| 2020-02-06 | 875045 | BIIB | 10-K | Url |
| 2019-10-22 | 875045 | BIIB | 10-Q | Url |
| 2019-07-24 | 875045 | BIIB | 10-Q | Url |
| 2019-04-24 | 875045 | BIIB | 10-Q | Url |
| 2019-02-06 | 875045 | BIIB | 10-K | Url |
| 2018-10-23 | 875045 | BIIB | 10-Q | Url |
| 2018-07-24 | 875045 | BIIB | 10-Q | Url |
| 2018-04-24 | 875045 | BIIB | 10-Q | Url |
| 2018-02-01 | 875045 | BIIB | 10-K | Url |
| 2017-10-24 | 875045 | BIIB | 10-Q | Url |
| 2017-07-25 | 875045 | BIIB | 10-Q | Url |
| 2017-04-25 | 875045 | BIIB | 10-Q | Url |
| 2017-02-02 | 875045 | BIIB | 10-K | Url |
| 2016-10-26 | 875045 | BIIB | 10-Q | Url |
| 2016-07-21 | 875045 | BIIB | 10-Q | Url |
| 2016-04-21 | 875045 | BIIB | 10-Q | Url |
| 2016-02-03 | 875045 | BIIB | 10-K | Url |
| 2015-10-21 | 875045 | BIIB | 10-Q | Url |
| 2015-07-24 | 875045 | BIIB | 10-Q | Url |
| 2015-04-24 | 875045 | BIIB | 10-Q | Url |
| 2015-02-04 | 875045 | BIIB | 10-K | Url |
| 2014-10-22 | 875045 | BIIB | 10-Q | Url |
| 2014-07-23 | 875045 | BIIB | 10-Q | Url |
| 2014-04-23 | 875045 | BIIB | 10-Q | Url |
| 2014-02-06 | 875045 | BIIB | 10-K | Url |
| 2013-10-28 | 875045 | BIIB | 10-Q | Url |
| 2013-07-25 | 875045 | BIIB | 10-Q | Url |
| 2013-04-25 | 875045 | BIIB | 10-Q | Url |
| 2013-02-05 | 875045 | BIIB | 10-K | Url |
| 2012-10-25 | 875045 | BIIB | 10-Q | Url |
| 2012-07-24 | 875045 | BIIB | 10-Q | Url |
| 2012-05-01 | 875045 | BIIB | 10-Q | Url |
| 2012-02-03 | 875045 | BIIB | 10-K | Url |
| 2011-10-28 | 875045 | BIIB | 10-Q | Url |
| 2011-07-26 | 875045 | BIIB | 10-Q | Url |
| 2011-04-21 | 875045 | BIIB | 10-Q | Url |
| 2011-02-04 | 875045 | BIIB | 10-K | Url |
| 2010-10-26 | 875045 | BIIB | 10-Q | Url |
| 2010-07-20 | 875045 | BIIB | 10-Q | Url |
| 2010-04-20 | 875045 | BIIB | 10-Q | Url |
| 2010-02-09 | 875045 | BIIB | 10-K | Url |
| 2009-10-21 | 875045 | BIIB | 10-Q | Url |
| 2009-07-17 | 875045 | BIIB | 10-Q | Url |
| 2009-04-17 | 875045 | BIIB | 10-Q | Url |
| 2009-02-06 | 875045 | BIIB | 10-K | Url |
| 2008-10-21 | 875045 | BIIB | 10-Q | Url |
| 2008-07-22 | 875045 | BIIB | 10-Q | Url |
| 2008-04-23 | 875045 | BIIB | 10-Q | Url |
| 2008-02-14 | 875045 | BIIB | 10-K | Url |
| 2007-10-23 | 875045 | BIIB | 10-Q | Url |
| 2007-07-24 | 875045 | BIIB | 10-Q | Url |
| 2007-05-03 | 875045 | BIIB | 10-Q | Url |
| 2007-02-21 | 875045 | BIIB | 10-K | Url |
| 2006-11-09 | 875045 | BIIB | 10-Q | Url |
| 2006-08-10 | 875045 | BIIB | 10-Q | Url |
| 2006-05-10 | 875045 | BIIB | 10-Q | Url |
| 2006-03-03 | 875045 | BIIB | 10-K | Url |
| 2005-11-02 | 875045 | BIIB | 10-Q | Url |
| 2005-07-27 | 875045 | BIIB | 10-Q | Url |
| 2005-04-29 | 875045 | BIIB | 10-Q | Url |
| 2005-03-31 | 875045 | BIIB | 10-K | Url |
Biogen Inc(NASDAQ:BIIB) 
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to ...
Website: http://www.biogen.com
Founded: 1978
Full Time Employees: 7,400
Sector: Healthcare
Industry: Drug Manufacturers-General
The information provided in this report about BIIB stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.